Editorial
Matching treatment to the genetic basis of (lipid) disorder in patients with coronary artery disease
| The first 150 words of the full text of this article appear below. |
Most people of old age in the western society have atherosclerosis to a greater or lesser extent; the condition can almost be regarded as a normal consequence of aging.1 Therefore, the clinical problem of atherosclerosis may be better described by the term "accelerated" atherosclerosis, which reflects the fact that some patients suffer earlier than most from an atherosclerotic process. It is this acceleration of atherosclerotic disease progression that is usually the subject of investigation.
Establishing the rate of progression of coronary atherosclerosis in
patients is important as progression of the disease is one of the major
factors that determines clinical prognosis.2 3 Therefore,
identifying patients at risk for increased progression of coronary
artery disease (CAD) is important as these patients might benefit from
early (lipid lowering) treatment. Thus far, it has proved difficult to
identify patients at increased risk when lipoprotein disturbances are
moderate, which is the case for most patients
This article has been cited by other articles:
-
WILKINS, M. R, ROSES, A. D, CLIFFORD, C P.
(2000). Pharmacogenetics and the treatment of cardiovascular disease. Heart
84: 353-354
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
